IGHV3OR15-7

Across TCGA pan-cancer cohorts, IGHV3OR15-7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGHV3OR15-7 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher IGHV3OR15-7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV3OR15-7 expression acts as an unfavorable survival marker.

OV, LUSC, and GBM are the cancer types where IGHV3OR15-7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
GBM	OS	Median	All	0.104	0.415	.024	3	view →
LUAD	OS	Median	All	0.188	0.670	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGHV3OR15-7–OV (DFS)

Open the OV breakdown →